Treatment of shoulder osteoarthritis and rotator cuff tears with bone marrow concentrate and whole bone marrow injections

Darrow, Marc; Shaw, Brent; Nicholas, Schmidt; Boeger, Gabrielle; Budgett, Saskia

doi:10.1080/2331205x.2019.1628883

Cited by 11 publications

(17 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, five studies were excluded being congress abstracts, one study was excluded because it was a case report [25], and one study was excluded because it provided the same data of another included study [26]. Thus, a total of 22 studies were included in the qualitative data synthesis: 4 preclinical studies [27][28][29][30] and 18 clinical studies [31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48]. Since the first reports in 2014, the publication trend remarkably increased over time, especially for the clinical studies, with over 50% of the articles published from 2018 ( Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Out of the 18 clinical articles found (Table 2), six were retrospective case series, five were retrospective comparative studies, four were randomized controlled trials (RCTs), and three were prospective case series. Eleven studies focused on knee OA [31][32][33][34][35][36][37][38][39][40][41], two focused on hip OA [42,43], two focused on shoulder OA [44,45], while the other three studies described several joints affected by OA [46][47][48]. Intra-articular BMAC injections were performed in 17 studies, while in one study [36], the injection was performed within the tibial and femoral subchondral bone of the knee.…”

Section: Clinical Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Bone marrow concentrate injections for the treatment of osteoarthritis: evidence from preclinical findings to the clinical application

Cavallo

Boffa

Andriolo

et al. 2020

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

Purpose To investigate the available literature on the use of bone marrow aspirate concentrate (BMAC) and summarize the current evidence supporting its potential for the injective treatment of joints affected by osteoarthritis (OA). Methods A systematic literature search was conducted on three electronic databases (PubMed, Embase, and Cochrane Library) in April 2020, using the following string: "((bone marrow concentrate) OR (BMC) OR (bone marrow aspirate concentrate) OR (BMAC)) AND (osteoarthritis)", and inclusion criteria: clinical and preclinical (animal) studies of any level of evidence, written in English language, and evaluating the intra-articular or subchondral use of BMAC for the injective treatment of OA joints. Results The publication trend remarkably increased over time. A total of 22 studies were included in the qualitative data synthesis: four preclinical studies and 18 clinical studies, for a total number of 4626 patients. Safety was documented by all studies, with a low number of adverse events. An overall improvement in pain and function was documented in most of the studies, but the clinical studies present significant heterogeneity, few patients, short-term follow-up, and overall poor methodology. Conclusion There is a growing interest in the field of BMAC injections for the treatment of OA, with promising results in preclinical and clinical studies in terms of safety and effectiveness. Nevertheless, the current knowledge is still preliminary. Preclinical research is still needed to optimize BMAC use, as well as high-level large controlled trials to better understand the real potential of BMAC injections for the treatment of patients affected by OA.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Clinical Studiesmentioning

confidence: 99%

Bone marrow concentrate injections for the treatment of osteoarthritis: evidence from preclinical findings to the clinical application

Cavallo

Boffa

Andriolo

et al. 2020

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

show abstract

“…Lately, Darrow et al reported on patients treated for shoulder osteoarthritis or rotator cuff tears (N = 50), with either BMC or BMA injections. Patients were grouped in receiving one or two injections [122]. Outcome reports included resting pain, active pain, upper extremity functionality scale, and overall improvement percentage.…”

Section: Shoulder Disordersmentioning

confidence: 99%

The Rationale of Autologously Prepared Bone Marrow Aspirate Concentrate for use in Regenerative Medicine Applications

Everts¹,

Flanagan²,

Rothenberg³

et al. 2020

Regenerative Medicine

View full text Add to dashboard Cite

Autologously prepared bone marrow aspirate concentrates, have the potential to play an adjunctive role in various patient pathologies that have not been able to heal with conventional treatment modalities. The use of bone marrow aspirate (BMA) and concentrates in regenerative medicine treatment plans and clinical applications is based on the fact that bone marrow cells, including progenitor and nucleated cells, platelets, and other cytokines, support in tissue healing and tissue regenerative processes. The use of concentrated BMA cells focuses primarily on mesenchymal stem cells (MSCs), with the ability to self-renew and differentiate into multiple cell types. Concentrated bone marrow cells can be retrieved from harvested BMA and ensuing minimal manipulative cell processing techniques, executed at point of care (POC). The application of bone marrow biological therapies may offer solutions in musculoskeletal pathologies, spinal disorders, chronic wound care, and critical limb ischemia (CLI), to effectively change the local microenvironment to support in tissue healing and facilitate tissue regeneration. This chapter will address the cellular content of bone marrow tissue, harvesting and preparation techniques, and discuss the biological characteristics of individual marrow cells, their inter-connectivity, and deliberate on the effects of BMA concentration.

show abstract

“…Glenohumeral arthritis is the sequela of variable pathological shoulder processes, with primary glenohumeral osteoarthritis being the most common, but could also be secondary to post‐traumatic arthritis, inflammatory arthritis and rotator cuff tear arthropathy. Patients with glenohumeral arthritis commonly show patterns of humeral and glenoid bone wear, with the erosion and deformity being caused by the etiology of the arthritis (Darrow, Shaw, Schmidt, Boeger, & Budgett, 2019; Grogan & Jobin, 2019; Neer, 1974). The magnitude of degenerative arthritis of the glenoid vary considerably and is based on the type of the arthritic process affecting the glenohumeral joint (Ansok & Muh, 2018; Cofield, 2007; Matsen, Bicknell, & Lippitt, 2007; Walch et al, 1998).…”

Section: Glenoid Deformity In Osteoarthritis and Its Surgical Managementmentioning

confidence: 99%

The glenoid and humeral head in shoulder osteoarthritis: A comprehensive review

Alashkham

Soames

2020

Clinical Anatomy

View full text Add to dashboard Cite

The key management of glenohumeral osteoarthritis is shoulder arthroplasty which aims to reduce pain and restore full shoulder function: it has increased in recent years. A detailed understanding of the anatomy of the glenoid and humeral head, as well as morphological changes of the glenoid in osteoarthritis, are important factors to consider when deciding on replacement components. This review begins with a brief introduction of the glenohumeral joint itself, and then considers the detailed anatomy of the glenoid fossa and humeral head, both of which are reported to have variable morphology. Several studies have been undertaken to assess various parameters, especially of the glenoid fossa including its shape, height, width, and articular surface area, version and inclination, in an attempt to define a standard classification that can be applied to surgical intervention. Nevertheless, no definitive consensus concerning the classification of these morphologies has been forthcoming, hence the need for this review. Following a consideration of these morphologies, the current state of knowledge regarding glenoid deformity in osteoarthritis, as well as its surgical management, is considered.

show abstract

Treatment of shoulder osteoarthritis and rotator cuff tears with bone marrow concentrate and whole bone marrow injections

Cited by 11 publications

References 33 publications

Bone marrow concentrate injections for the treatment of osteoarthritis: evidence from preclinical findings to the clinical application

Bone marrow concentrate injections for the treatment of osteoarthritis: evidence from preclinical findings to the clinical application

The Rationale of Autologously Prepared Bone Marrow Aspirate Concentrate for use in Regenerative Medicine Applications

The glenoid and humeral head in shoulder osteoarthritis: A comprehensive review

Contact Info

Product

Resources

About